News Column

Recent Data from L.R. Desnoyers and Co-Authors Highlight Findings in Receptor Protein-Tyrosine Kinases (Tumor-specific activation of an...

August 27, 2014

Recent Data from L.R. Desnoyers and Co-Authors Highlight Findings in Receptor Protein-Tyrosine Kinases (Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Membrane Proteins have been published. According to news reporting from South San Francisco, California, by NewsRx journalists, research stated, "Target-mediated toxicity constitutes a major limitation for the development of therapeutic antibodies. To redirect the activity of antibodies recognizing widely distributed targets to the site of disease, we have applied a prodrug strategy to create an epidermal growth factor receptor (EGFR)-directed Probody therapeutic-an antibody that remains masked against antigen binding until activated locally by proteases commonly active in the tumor microenvironment."

The news correspondents obtained a quote from the research, "In vitro, the masked Probody showed diminished antigen binding and cell-based activities, but when activated by appropriate proteases, it regained full activity compared to the parental anti-EGFR antibody cetuximab. In vivo, the Probody was largely inert in the systemic circulation of mice, but was activated within tumor tissue and showed antitumor efficacy that was similar to that of cetuximab. The Probody demonstrated markedly improved safety and increased half-life in nonhuman primates, enabling it to be dosed safely at much higher levels than cetuximab. In addition, we found that both Probody-responsive xenograft tumors and primary tumor samples from patients were capable of activating the Probody ex vivo."

According to the news reporters, the research concluded: "Probodies may therefore improve the safety profile of therapeutic antibodies without compromising efficacy of the parental antibody and may enable the wider use of empowered antibody formats such as antibody-drug conjugates and bispecifics."

For more information on this research see: Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Science Translational Medicine, 2013;5(207):207ra144 (see also Membrane Proteins).

Our news journalists report that additional information may be obtained by contacting L.R. Desnoyers, CytomX Therapeutics Inc, 343 Oyster Point Boulevard, Suite 100, South San Francisco, CA 94080, United States. Additional authors for this research include O. Vasiljeva, J.H. Richardson, A. Yang, E.E. Menendez, T.W. Liang, C. Wong, P.H. Bessette, K. Kamath, S.J. Moore, J.G. Sagert, D.R. Hostetter, F. Han, J. Gee, J. Flandez, K. Markham, M. Nguyen, M. Krimm and Wong.

Keywords for this news article include: Antibodies, Therapy, Protease, California, Immunology, United States, Blood Proteins, Immunoglobulins, Protein Kinases, Membrane Proteins, South San Francisco, Phosphotransferases, Enzymes and Coenzymes, North and Central America, Epidermal Growth Factor Receptor, Receptor Protein Tyrosine Kinases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters